FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type	Responses	s)															
1. Name and Address of Reporting Person * Touchon Pascal					2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director 10% Owner					
(Last) (First) (Middle) C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900				06/	3. Date of Earliest Transaction (Month/Day/Year) 06/25/2021						X Officer (give title below) Other (specify below) President and CEO						
(Street) SOUTH SAN FRANCISCO, CA 94080				4. I	4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	AN FRA	(State)	ZA 94080 (Zip)			т	able I -	Non-	Derive	ative S	Securitie	es A can	ired Disn	osed of or l	Reneficially	Owned	
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Y	ear) Exec	2A. Deemed Execution Date, if		3. Transac Code (Instr. 8)					uired of (D)	Reported Transaction(s)		ties Following	6. Ownership Form:	Beneficial	
			(Moi			Cod	e ·	V An	nount	(A) or (D)	Price	(Instr. 3	and 4)		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	
Common Stock		06/25/2021				S(1)	14	,194	D 3	\$ 16.32	345,11	1		D		
			Tabl					tl quired	he for	m dis	splays a	n curre	ently valid	OMB con	spond unle trol numbe		
(Instr. 3) Pr		3. Transaction Date (Month/Day/Y	Year) Execution D	emed on Date, if			5. Number		•		7. 7 An Un Sec	Fitle and aount of derlying curities str. 3 and	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form o Derivat Security Direct (or Indir	Benefic Owners (Instr. 4	
					Code	V	(A)		Date Exercis		Expiration Date	on Tit	Amount or Number of Shares				
Reporti	ing O	wners															

		Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Touchon Pascal C/O ATARA BIOTHERAPEUTICS, INC 611 GATEWAY BLVD., SUITE 900 SOUTH SAN FRANCISCO, CA 94080	X		President and CEO					

Signatures

/s/ David Tucker, Attorney-in-Fact for Pascal Touchon	06/29/2021	
**Signature of Reporting Person	Date	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.